RGCIRC (Rajiv Gandhi Cancer Institute & Research Centre) successfully concluded FESTOMICS – 2, a two-day academic programme focused on “Precision Through Omics,” held on January 30 and 31, 2026, at RGCIRC, Rohini. Building on the momentum of its first edition held last year, FESTOMICS – 2 brought together leading experts in pathology, molecular diagnostics, oncology and translational research to discuss the expanding role of omics-based technologies in modern cancer care.
The conference served as a comprehensive platform to examine how genomics, transcriptomics, epigenetics and metabolomics are reshaping cancer diagnosis, risk stratification and treatment selection. With strong participation from clinicians, pathologists, laboratory scientists and trainees, the programme reflected the growing importance of molecular integration in routine oncology practice.
The academic sessions covered a wide spectrum of topics, including advances in cancer genomics, next-generation sequencing (NGS), PCR-based diagnostics, fluorescence in situ hybridisation (FISH), liquid biopsy, methylation classifiers, metabolomics and the interpretation of complex molecular reports. The sessions focused on practical challenges in molecular diagnostics, such as quality control, panel selection, data interpretation and clinical relevance, reinforcing the need for precision with responsibility.
A key emphasis throughout FESTOMICS – 2 was the integration of molecular data into clinical decision-making. Case-based discussions highlighted how molecular insights can guide therapeutic choices, refine prognostication and support multidisciplinary tumour board deliberations across solid tumours and hematological malignancies. Experts also addressed emerging biomarkers in breast cancer, lung cancer, prostate cancer, sarcomas, thyroid cancer and paediatric malignancies, underscoring the breadth of omics applications.
Speaking on the occasion, Dr. (Col. Retd.) Anurag Mehta, Principal Director, Laboratory Services & Transfusion Medicine at RGCIRC, and Organising Chairman of FESTOMICS – 2, emphasised the translational value of the discussions. “Molecular diagnostics and omics-based technologies are no longer confined to research laboratories; they are now an integral part of oncology practice. The objective of FESTOMICS is to bridge the gap between complex molecular data and meaningful clinical decision-making, so that advances in genomics and precision diagnostics ultimately translate into evidence based individualised care for the oncology patients,” he noted.
The programme featured distinguished faculty from premier institutions across India, including premier oncology centres & tertiary cancer care centres and diagnostic laboratories, fostering a rich exchange of perspectives between molecular science and clinical oncology. Interactive sessions and panel discussions encouraged active participation and highlighted the importance of multidisciplinary discussion for the optimal management of the patient.
FESTOMICS – 2 reaffirmed RGCIRC’s leadership in advancing precision oncology education and its commitment to bridging the gap between cutting-edge molecular research and real-world clinical practice. Through initiatives such as FESTOMICS, the institute continues to strengthen capacity building, promote evidence-based diagnostics and support the evolving landscape of personalized cancer care in India.
The conference concluded with closing remarks by Dr. Sunil Pasricha, Sr. Consultant, Histopathology, RGCIRC and the organizing secretary for the event that reinforced the need for continued learning, ethical application of molecular technologies and patient-centred integration of innovation, echoing RGCIRC’s guiding values of Ethics, Empathy and Excellence.
